Day One Biopharmaceuticals' (DAWN) "Outperform" Rating Reaffirmed at Wedbush

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at Wedbush in a report released on Tuesday, RTT News reports. They currently have a $33.00 price objective on the stock. Wedbush's price objective points to a potential upside of 93.21% from the company's current price.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an "overweight" rating in a research report on Monday, April 22nd. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a research report on Tuesday, February 27th. Oppenheimer restated a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. HC Wainwright reduced their price target on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.67.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock traded up $0.48 during mid-day trading on Tuesday, reaching $17.08. The company's stock had a trading volume of 1,776,926 shares, compared to its average volume of 891,229. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $18.07. The company has a market capitalization of $1.49 billion, a P/E ratio of -7.04 and a beta of -1.44. The firm's fifty day moving average price is $15.47 and its two-hundred day moving average price is $14.12.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). On average, research analysts predict that Day One Biopharmaceuticals will post -2.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Samuel C. Blackman sold 2,258 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 7,615 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the transaction, the chief executive officer now directly owns 721,813 shares of the company's stock, valued at $11,007,648.25. The disclosure for this sale can be found here. Insiders sold 195,247 shares of company stock valued at $3,376,817 over the last three months. Insiders own 8.40% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company's stock valued at $56,807,000 after buying an additional 346,090 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 38.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company's stock valued at $5,486,000 after buying an additional 125,050 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company's stock valued at $2,703,000 after buying an additional 40,387 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company's stock valued at $14,020,000 after purchasing an additional 336,910 shares during the period. Finally, Deutsche Bank AG lifted its position in Day One Biopharmaceuticals by 5.5% during the third quarter. Deutsche Bank AG now owns 177,137 shares of the company's stock valued at $2,173,000 after purchasing an additional 9,219 shares during the period. Hedge funds and other institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.